Peer-reviewed veterinary case report
CT scan blood flow in dogs with nasal tumors
By Mortier, Jeremy R et al.·Published in Journal of veterinary internal medicine·2023·Small Animal Teaching Hospital, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Dynamic contrast-enhanced computed tomography in dogs with nasal tumors.
- Species:
- dog
Plain-English summary
A group of 24 dogs with nasal tumors, including both epithelial tumors and sarcomas, underwent a special imaging test called dynamic contrast-enhanced computed tomography (DCECT) to evaluate their tumors before and during radiotherapy. The results showed that nasal sarcomas had lower blood flow and blood volume compared to nasal carcinomas, and while epithelial tumors tended to shrink during treatment, sarcomas often increased in size. Unfortunately, the changes in blood flow and volume did not predict how long the dogs would survive. This information can help veterinarians understand the differences between tumor types and their responses to treatment.
People also search for: dog nasal tumor treatment · nasal sarcoma in dogs · DCECT for dog tumors · dog radiotherapy side effects · dog cancer survival rates
Abstract
BACKGROUND: Treatment of nasal tumors in dogs is associated with high morbidity and reliable prognostic factors are lacking. Dynamic contrast-enhanced computed tomography (DCECT) can be used to assess tumor perfusion. OBJECTIVES: To assess perfusion parameters of nasal tumors (correlating with tumor type) before and during radiotherapy (RT) and find potential correlation with survival. ANIMALS: Twenty-four client-owned dogs with nasal tumors, including 16 epithelial tumors and 8 sarcomas. METHODS: Prospective cross-sectional study. All dogs had baseline DCECT to assess fractional vascular volume (BV), blood flow (BF), and transit time (TT). Thirteen dogs had repeat DCECT after 12 Gy of megavoltage RT. Survival times were calculated. RESULTS: Median BV was 17.83 mL/100 g (range, 3.63-66.02), median BF was 122.63 mL/100 g/minute (range, 23.65-279.99), and median TT was 8.91 seconds (range, 4.57-14.23). Sarcomas had a significantly lower BF than adenocarcinomas (P = .002), carcinomas (P = .01), and other carcinomas (P = .001), and significantly lower BV than adenocarcinomas (P = .03) and other carcinomas (P = .004). Significant associations were found between epithelial tumors and sarcoma for change in tumor volume (P = .01), width (P = .004), and length (P = .02) in that epithelial tumors decreased in volume whereas sarcomas increased in volume. Perfusion parameters were not correlated with survival. CONCLUSIONS AND CLINICAL IMPORTANCE: Nasal sarcomas have lower BV and BF than nasal carcinomas, and sarcomas have a lower size reduction than carcinomas early on during RT. Baseline results and changes in perfusion parameters may not be correlated with survival.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/37092693/